NCT04724941 Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
| NCT ID | NCT04724941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Schleswig-Holstein |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2021-06-01 |
| Primary Completion | 2027-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.
Eligibility Criteria
Inclusion Criteria: * Age between 50 and 99 Exclusion Criteria: * Presence of clinical PD at the time of study inclusion * Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis) * other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment * in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.